Amphastar Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
AMPH$29.06-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
(in thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| · 2025 · · 2024 · · 2023 | |||||||||
| Net income | | $98,094 | | $159,519 | | $137,545 | |||
| | | | | | | | | | |
| Other comprehensive income (loss), net of income taxes | | | | | | | | | |
| Foreign currency translation adjustment | | 3,867 | | (695) | | 298 | |||
| Change in pension obligations | | — | | | (8) | | | (152) | |
| Total other comprehensive income (loss) | | 3,867 | | (703) | | 146 | |||
| | | | | | | | | | |
| Total comprehensive income | | $101,961 | | $158,816 | | $137,691 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.